Imunoterapi untuk kanker payudara di República da Coreia — dapatkan 3 klinik yang cocok dengan biayanya

In South Korea, immunotherapy primarily treats triple-negative breast cancer (TNBC). TNBC is an aggressive subtype lacking specific hormone receptors. Leading Seoul facilities include JCI-accredited Severance Hospital and Seoul National University Hospital. They use drugs like Pembrolizumab (Keytruda) combined with chemotherapy for early-stage or metastatic triple-negative cases.

• Triple-negative cancer: Main target for checkpoint inhibitors like Keytruda in Korea.
• Clinical benchmarks: Seoul National University Hospital reports 91.9% breast cancer survival rates.
• Advanced staging: Treats metastatic tumours expressing high levels of the PD-L1 protein.
• Research integration: Clinics often incorporate protocols like KeyNote 522 for Stage 2–3 patients.

Bookimed Expert Insight: South Korea is a global leader in clinical oncology research. Seoul National University Hospital performs 1,200+ breast tumour removals annually. Data shows Korean centres often integrate emerging research like tertiary lymphoid structure analysis. This helps specialists pinpoint which 20% of TNBC patients will likely respond best to immunotherapy.

Patient Consensus: Patients with triple-negative breast cancer find the KeyNote 522 protocol effective in Korea. Clinical teams often combine immunotherapy with physiotherapy and nutritional support during recovery.

Common side effects of immunotherapy for breast cancer in Korea include fatigue, skin rashes, and gastrointestinal issues like diarrhoea. Checkpoint inhibitors like pembrolizumab empower the immune system. However, they may also trigger inflammation in healthy organs. Leading Seoul centres specialise in early detection of these immune-related adverse events.

• Fatigue management: Extreme tiredness often lasts for one week after drug administration.
• Endocrine monitoring: Thyroid issues are common and require regular blood tests for TSH.
• Dermatological effects: Patients frequently report dry skin, rashes, or persistent itching.
• Gastrointestinal care: Intestinal inflammation or colitis may occur, sometimes requiring hospitalisation.
• Infusion reactions: Some experience fever, chills, or dizziness during the actual treatment.

Bookimed Expert Insight: While immunotherapy is often cheaper in Korea than Australia, patients should account for combination therapy costs. Seoul National University Hospital maintains a 91.9% breast cancer survival rate. Their specialists often use digital safety systems to track side effects in real time. This helps prevent minor reactions from becoming severe.

Patient Consensus: Expect post-infusion swelling in your hands and feet for up to five days. Regular monitoring for thyroid changes and joint pain is essential during your stay in Korea.

The latest approved therapies in Korea for 2026 focus on advanced Antibody-Drug Conjugates. These include Datopotamab deruxtecan and combination protocols using Pembrolizumab. These treatments target metastatic triple-negative and HER2-positive subtypes. They are offered at JCI-accredited Seoul centres such as Severance Hospital and Seoul National University Hospital.

• Targeted antibodies: Datopotamab deruxtecan serves as a 2026 advancement for metastatic triple-negative cases.
• Combination protocols: Keytruda paired with Trodelvy offers first-line therapy for PD-L1-positive patients.
• HER2 expansion: Enhertu use has expanded into earlier neoadjuvant and adjuvant treatment lines.
• Advanced diagnostics: Vepdegestrant targets ER+/HER2- disease, guided by specific Guardant360 biomarker testing.

Bookimed Expert Insight: Seoul National University Hospital reports a 91.9% breast cancer survival rate, which exceeds US averages. This high success stems from rapid adoption of international standards. Major centres like Severance often implement FDA-cleared therapies early. This can happen months before local insurance subsidies are finalised.

Patient Consensus: Patients find that advanced immunotherapy in the Republic of Korea is available but often self-funded. Doctors recommend verifying BRCA1/2 mutation status for PARP inhibitor options. Specialist centres provide 24/7 interpreters for Australians.

South Korea hosts numerous clinical trials for breast cancer immunotherapy. These trials focus on advanced treatments like sacituzumab govitecan for triple-negative cases. Major centres in Seoul participate in global studies. These studies investigate immune checkpoint blockades and combination therapies. They focus on patients who have relapsed after initial treatment.

• Advanced therapies: Trials like TROPION-Breast02 explore options for PD-L1 negative and relapsed patients.
• Approved options: Sacituzumab govitecan is already approved and reimbursed for second-line triple-negative treatment.
• Specialised centres: Seoul National University Hospital (SNUH) achieves a 91.9% breast cancer survival rate.
• Clinical research: Leading hospitals like Severance partner with MD Anderson to drive oncology research.

Bookimed Expert Insight: While immunotherapy costs from $4,500 to $8,500, the real value lies in clinical volume. Severance Hospital serves 4 million outpatients annually. This massive patient flow allows Korean centres to recruit for complex immunotherapy trials. They can recruit much faster than many Western facilities.

Patient Consensus: Patients in the Republic of Korea find combining laser-guided imaging and immunotherapy highly promising. Many recommend using the Clinical Research Information Service to find active trial locations across Seoul.

In the Republic of Korea, immunotherapy for breast cancer is typically given through intravenous infusions. Patients receive it in specialised oncology centres. Treatment often involves drugs like Pembrolizumab under the Keynote-522 protocol. It lasts between 6 and 12 months for earlier stages. For metastatic cases, it can continue for up to 2 years.

• Infusion method: Medication like Keytruda is delivered intravenously at specialised infusion centres in Seoul.
• Cycle frequency: Patients usually receive one infusion every 3 or 6 weeks during treatment.
• Session timing: Infusions take about 30 minutes, with 60 minutes of monitoring required afterwards.
• Combined approach: Therapies are often paired with chemotherapy before surgery to help shrink tumours.
• Maintenance phase: Treatment often continues for 6 months after surgery as single-agent immunotherapy.
• Survival outcomes: Seoul National University Hospital reports a 91.9% breast cancer survival rate.

Bookimed Expert Insight: Leading Seoul hospitals, such as Severance Hospital, have direct partnerships with top US centres. MD Anderson is one of them. This means patients receive the exact same protocols used in the West, such as the Keynote-522 regimen. However, they often get faster access to specialists and robotic technologies.

Patient Consensus: Patients find the 12-month commitment manageable. This is because the second half of the regimen involves immunotherapy alone, without the side effects of chemotherapy. Success is often linked to PD-L1 testing. This helps Korean oncologists predict how well the treatment will work.

National Health Insurance in South Korea covers Keytruda for specific breast cancer indications. This coverage is effective from early 2026. Coverage prioritises metastatic or locally recurrent triple-negative breast cancer expressing PD-L1 and high-risk early-stage cases. International patients typically pay full out-of-pocket costs without local insurance.

• Coverage scope: Insurance now applies to metastatic and high-risk early-stage triple-negative breast cancer.
• Patient co-payments: Residents generally pay 5% to 20% of costs for severe diseases.
• International costs: Immunotherapy typically costs from $4,500 to $8,500 for non-residents.
• Expert facilities: JCI-accredited centres like Severance Hospital partner with major US cancer institutions.

Bookimed Expert Insight: Insurance helps residents. However, international patients should look at large centres like Seoul National University Hospital. Their 91.9% breast cancer survival rate actually beats the US average. Clinics here often have dedicated teams. These teams help foreign patients navigate manufacturer assistance programs for high-cost drugs.

Patient Consensus: Hospitals in Seoul provide helpful interpreters. They can often assist with payment plans for large medical bills. Patients recommend triple-checking their specific tumour markers. Insurers strictly limit coverage to confirmed triple-negative cases.